Vascular Nanotransfer Technologies (“VNT”) Reports In Vivo Results for Its Paclitaxel Nano-Carrier Based Drug Coated Balloon (DCB) Technology  
10/26/2012 8:00:12 AM

AUBURNDALE, Mass.--(BUSINESS WIRE)--Vascular Nanotransfer Technologies (“VNT”) (, an emerging medical technology company, announced today that large animal model in vivo tests of its paclitaxel nanocarrier-based Drug Coated Balloon (“DCB”) achieved tissue levels comparable to devices with proven clinical efficacy.